Ovarian Cancer: Symptoms and Diagnosis

Ovarian cancer ranks as the fifth leading cause of cancer death among women in the United States, according to the National Cancer Institute, and its lethality is closely linked to the stage at which it is detected. This page covers the defining characteristics of ovarian cancer, the biological mechanisms that drive symptom emergence, the clinical scenarios that most commonly lead to diagnosis, and the decision thresholds that guide diagnostic workup. Understanding these elements is foundational to the broader field of oncology as a discipline.

Definition and Scope

Ovarian cancer is a malignancy originating in the tissues of the ovary, the fallopian tube, or the peritoneal surface of the pelvis. The American Cancer Society estimates approximately 19,680 new cases of ovarian cancer will be diagnosed in the United States in 2024, with roughly 12,740 deaths attributed to the disease in the same year.

The disease is classified into three primary histologic categories:

  1. Epithelial ovarian cancer — Accounts for approximately 90% of all ovarian malignancies (National Cancer Institute, SEER Program). Subtypes include high-grade serous carcinoma (the most common and aggressive form), low-grade serous carcinoma, clear cell carcinoma, endometrioid carcinoma, and mucinous carcinoma.
  2. Germ cell tumors — Arise from the egg-producing cells and represent roughly 5% of ovarian cancers. These affect predominantly younger women and carry a more favorable prognosis when treated promptly.
  3. Sex cord-stromal tumors — Originate from the connective tissue cells that produce hormones; they account for fewer than 5% of cases.

High-grade serous carcinoma is of particular diagnostic importance because it is frequently diagnosed at Stage III or IV, when disease has spread beyond the pelvis. The National Comprehensive Cancer Network (NCCN) maintains clinical practice guidelines for ovarian cancer classification and treatment planning.

How It Works

The pathological progression of ovarian cancer centers on uncontrolled cellular proliferation within the ovarian epithelium, fallopian tube epithelium, or peritoneal mesothelium. High-grade serous carcinoma is now understood by researchers, including those publishing in Gynecologic Oncology, to originate predominantly from the fimbriated end of the fallopian tube rather than from ovarian surface epithelium directly.

Symptoms emerge indirectly. As tumors enlarge or ascites (fluid accumulation in the abdominal cavity) develops, mechanical pressure is exerted on adjacent structures — the bladder, bowel, and diaphragm. This explains the characteristic cluster of symptoms:

These symptoms are nonspecific, overlapping considerably with irritable bowel syndrome and other gastrointestinal conditions, which contributes to diagnostic delay. The Society of Gynecologic Oncology (SGO) has noted that the median time from symptom onset to diagnosis often exceeds three months.

Genetic underpinning plays a measurable role: women carrying a pathogenic variant in BRCA1 carry a lifetime ovarian cancer risk of approximately 44%, and those with BRCA2 variants carry approximately 17% lifetime risk, according to data published by the National Human Genome Research Institute. Lynch syndrome is a separate hereditary pathway that elevates ovarian cancer risk through mismatch repair gene mutations. Genetic testing and counseling is therefore an integral part of evaluating women with a family history suggestive of hereditary cancer syndromes.

Common Scenarios

Three clinical presentations account for the majority of ovarian cancer diagnoses:

Incidental discovery on imaging. A pelvic ultrasound obtained for another indication — such as evaluation of uterine fibroids or pelvic pain — reveals an adnexal mass. The morphology, size, and internal characteristics of the mass (solid components, septations, vascularity) guide further evaluation under NCCN and American College of Radiology (ACR) guidance.

Symptomatic presentation in primary care. A woman presents with persistent bloating, early satiety, or pelvic discomfort lasting more than a few weeks. Guidelines from the SGO and NCCN recommend that when these symptoms occur more than 12 times per month, ovarian cancer must be included in the differential. The diagnostic pathway then proceeds to transvaginal ultrasound and serum CA-125 measurement.

Emergency presentation with advanced disease. In approximately 60% of cases, according to SEER Program data, ovarian cancer is not diagnosed until it has reached Stage III or IV. These patients may present to emergency departments with large-volume ascites, bowel obstruction, or pleural effusion. Cytoreductive surgery and platinum-based chemotherapy are standard treatment approaches at this stage. Imaging modalities used in these scenarios are detailed under imaging for cancer evaluation.

Decision Boundaries

The diagnostic workup for suspected ovarian cancer follows a structured algorithm with defined thresholds for escalation. The regulatory context for oncology practice in the United States includes FDA-cleared diagnostic tests and CMS reimbursement structures that shape which tests are used and when.

Key decision thresholds include:

  1. CA-125 threshold — A serum CA-125 level above 35 U/mL is commonly used as an abnormal cutoff in postmenopausal women (per standard laboratory reference ranges), but CA-125 is not sufficiently specific for screening in asymptomatic populations. Elevated CA-125 can occur in endometriosis, uterine fibroids, and other benign conditions.
  2. Ultrasound risk stratification — The ACR O-RADS (Ovarian-Adnexal Reporting and Data System) provides a standardized 5-category risk classification for adnexal lesions on ultrasound, ranging from O-RADS 1 (normal ovary) to O-RADS 5 (high risk of malignancy). An O-RADS score of 4 or 5 typically warrants referral to a gynecologic oncologist.
  3. ROMA score and Risk of Malignancy Index (RMI) — Multimarker algorithms combining CA-125, HE4 (human epididymis protein 4), and menopausal status improve pre-surgical stratification compared to CA-125 alone. HE4 is FDA-cleared for use in monitoring epithelial ovarian cancer.
  4. Surgical staging — Definitive diagnosis requires histopathologic confirmation from tissue obtained at surgery. The FIGO (International Federation of Gynecology and Obstetrics) staging system is the standard classification framework, with Stage I confined to the ovaries and Stage IV involving distant metastasis.
  5. Referral threshold — NCCN guidelines specify that any postmenopausal woman with a pelvic mass, or any premenopausal woman with a complex adnexal mass and elevated CA-125, should be evaluated by a gynecologic oncologist rather than a general surgeon or obstetrician-gynecologist.

Molecular profiling of tumor tissue at the time of diagnosis, including BRCA1/2 somatic testing and homologous recombination deficiency (HRD) assays, now informs treatment selection — particularly eligibility for PARP inhibitor maintenance therapy. This is addressed in detail under molecular profiling and biomarkers.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)